OR WAIT null SECS
November 03, 2020
Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.
November 02, 2020
Experts fear confusion over allocation processes, cold-chain requirements, and IT systems needed to bring a COVID-19 vaccine to market.
October 30, 2020
The Center for Drug Evaluation and Research is studying factors that influence the development of generic versions of brand-name drugs.
The agency published clinical data on remdesivir and information about COVID-19 treatments that have received scientific advice or informal guidance from EMA’s pandemic Task Force.
October 29, 2020
Through the agreement, Takeda will handle securing the regulatory approvals before distributing the doses, while Moderna will supply the finished product.
October 28, 2020
The companies have signed a Statement of Intent with Gavi to make 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine available for distribution.
October 27, 2020
The Phase III clinical trial of NVX-CoV2373 is expected to be fully enrolled in the UK and will begin in the US and Mexico by the end of November 2020.
The new premix can be used with tablets and a range of other solid oral dosage forms.
October 22, 2020
The agency’s Vaccines and Related Biological Products Advisory Committee met to discuss COVID-19 vaccine approvals, post-marketing safety studies, and ongoing safety monitoring of vaccines.
October 20, 2020
OptiGel DR softgel capsules are formed by the combination of pectin, a naturally derived polysaccharide, and gelatin, which eliminates the need for a separate capsule coating step.